Integer (ITGR) 2024 Truist Securities MedTech Conference summary

Strategic focus and market positioning

• Prioritizing growth in four key medtech submarkets: electrophysiology, structural heart, neurovascular, and neuromodulation, with a focus on vertical integration and supply chain consolidation.

• Serving major industry players and maintaining a diversified customer base, with half of sales in cardiovascular and 40% in cardiac rhythm management and neuromodulation.

• Actively exiting non-core segments to sharpen focus on high-growth medical device markets.

• Strategy aims to accelerate top-line growth by shifting sales mix toward faster-growing end markets.

Financial objectives and growth outlook

• Targeting organic revenue growth 200 basis points above the 4%-6% market average, aiming for 6%-8% annually.

• Operating profit growth goal is 2x sales growth, targeting 12%-16% annually as sales expand.

• Maintaining debt leverage between 2.5 and 3.5 to support ongoing tuck-in acquisitions.

• M&A strategy focuses on acquiring companies with presence and pipelines in the four priority markets, seeking accretive growth and margins.

Visibility, guidance, and risk management

• Entered the year with over $900 million in orders, providing strong six-month visibility and rolling 12-month demand forecasts from customers.

• Financial guidance is risk-adjusted based on historical analysis of customer optimism and actual outcomes.

• Near-term guidance reflects best estimates with a plus or minus range; full-year guidance is more conservatively risk-adjusted.

• Customer order changes are common but typically have minor impact due to diversified exposure and flexible planning.